Charles Schwab Investment Management Inc. Boosts Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Charles Schwab Investment Management Inc. raised its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 9.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,959,256 shares of the company’s stock after buying an additional 248,318 shares during the period. Charles Schwab Investment Management Inc. owned about 0.65% of GE HealthCare Technologies worth $231,355,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Mesirow Financial Investment Management Inc. raised its position in shares of GE HealthCare Technologies by 39.6% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 4,084 shares of the company’s stock worth $383,000 after purchasing an additional 1,159 shares during the last quarter. Cathy Pareto & Associates Inc. purchased a new stake in GE HealthCare Technologies during the 4th quarter worth approximately $670,000. LMR Partners LLP acquired a new position in shares of GE HealthCare Technologies during the third quarter valued at approximately $7,387,000. Principal Financial Group Inc. lifted its position in shares of GE HealthCare Technologies by 1.9% in the third quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company’s stock valued at $94,780,000 after acquiring an additional 19,010 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of GE HealthCare Technologies in the third quarter worth approximately $1,396,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on GEHC. Wells Fargo & Company increased their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. Finally, Citigroup boosted their price target on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $97.67.

GE HealthCare Technologies Stock Performance

NASDAQ:GEHC opened at $85.41 on Friday. The company’s 50-day moving average is $86.63 and its two-hundred day moving average is $86.13. The firm has a market capitalization of $39.06 billion, a price-to-earnings ratio of 19.73, a PEG ratio of 3.19 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. Analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.